Introduction
Dual infection of the genital tract with Chlamydia trachomatis and Neisseria gonorrhoeae is well established with a prevalence ranging from 14-43% but little is known of the epidemiology and associated clinical features of such coexisting infections.
1 Recently a gene, sac-4, was found in a high proportion of gonococcal isolates from patients with coexisting chlamydial infection and it was postulated that sac-4 increased the risk of development of mixed gonococcal and chlamydial infection.
2 This gene conferred stable (not lost on subculture) complement factor C1q dependent serum resistance in gonococci. 3 4 The aims of this study were to use the polymerase chain reaction (PCR) assay described by Nowicki et al 2 3 to determine the frequency of the sac-4 gene in a larger range of isolates of diVerent serovars; and to assess the prevalence of sac-4 in gonococcal isolates from patients with and without coexisting chlamydial infection.
Materials and methods

PATIENTS AND ISOLATES
Isolates from 259 episodes of gonorrhoea in 80 female and 179 male patients attending a genitourinary medicine (GUM) clinic were studied. The isolates represented 19 diVerent serovars. The prevalence of sac-4 was determined for each of the common serovars, arbitrarily defined as comprising more than 15 isolates each: serovars represented by less than 15 isolates were grouped together as "other 1A" and "other 1B" serovars (see table 1 ). The presence of coexisting chlamydial infection was determined from laboratory and GUM clinical records.
EXTRACTION OF DNA AND PCR ASSAY
The growth from an overnight plate culture was mixed with 1 ml of saline, centrifuged, resuspended in 200 µl of distilled water, and heated for 20 minutes at 100°C. After cooling and centrifugation the supernatant from each tube was stored at −20°C for PCR testing. A volume of 2 µl of DNA template was added to 100 µl reaction mix (50 mM KCl, 10 mM TRIS-HCl, 15 mM MgCl 2 and 0.1% Triton X-100) containing 0.5 units of Taq Polymerase (Promeg Corporation, Southampton), 20 µmol of each DNTP (Promega), and 0.1 µmol of each primer (Oswel DNA Service, Southampton). The reaction mixture was overlaid with two drops of liquid paraYn. The amplification reaction consisted of 30 cycles of 1 minute denaturation at 92°C, 1 minute annealing at 55°C, and 1 minute extension at 72°C. An aliquot of 20 µl was removed for electrophoretic analysis on a 2% agarose gel. A band corresponding to 344 base pairs indicated a positive sac-4 result.
A sac-4 negative and positive control strain were included in each run.
STATISTICAL ANALYSIS
This was performed using exact logistic regression.
Results
PCR analysis showed that 149 isolates (57.5%) were sac-4 + (each strain gave a single band corresponding to 344 base pairs) and 110 isolates (42.5%) were sac-4 − (no bands present). An example of a typical gel is shown in figure 1 . The prevalence of sac-4 ranged from 34.9% in serovar 1B2 to 100% in serovar 1B18 (table 1) . The data in table 1 were analysed by exact logistic regression, with sac-4 as the response (dependent) variable, and chlamydia status and gonococcal serovar as independent (explanatory) factors with two and eight levels respectively. Comparing chlamydia positive with chlamydia negative patients unadjusted for serovar gave an odds ratio = 1.65, CI (0.8,3.47) p=0.2. This indicates that overall a higher prevalence of sac-4 was observed in gonococcal isolates from chlamydia positive patients than in isolates from chlamydia negative patients but the diVerence was not statistically significant. Comparing the prevalence of sac-4 in gonococcal isolates from chlamydia positive patients with chlamydia negative patients adjusted for gonococcal serovar gave an odds ratio = 1.06 CI (0.42,2.6) p>0.9. Thus the slight excess of sac-4 prevalence in gonococcal isolates from chlamydia positive patients virtually disappears when the serovar of the infecting gonococcal isolate is taken into account.
Comparing the eVects of gonococcal serovar adjusted for the chlamydia status of the patient, the odds ratios compared with serovar 1A2 were: other 1A serovars 0.19 CI (0.01-1.44); 1B2 0.14 CI (0.01-0.74); 1B3 0.44 CI (0.06-2.29); 1B6 0.11 CI (0.002-1.06); 1B18 undefined (this group had 100% prevalence for sac-4); 1B31 4.34 CI 0.32-251.66); other 1B 0.33 (0.05-1.84). These results indicate significant diVerences in sac-4 prevalence between the serovar groups taking into account the chlamydia status of the patients. Exact logistic regression analysis for interaction between chlamydia status and gonococcal serovar yielded a p value of 0.05. Thus there is no evidence for diVerences between serovar groups in the comparison of sac-4 prevalences between the chlamydia positive and chlamydia negative patients.
Similar results were obtained using approximate logistic regression including the subjects with unknown chlamydia status.
Discussion
The majority of isolates, 57.5% (149/259) in our local population of gonococci, were sac-4 positive. However, the prevalence of sac-4 was not significantly higher (p=0.2) in gonococcal isolates from patients with coexisting chlamydial infection (69.5%) than in those without (57.9%). These findings suggest that sac-4 does not increase the risk of developing mixed infection with C trachomatis. Our findings diVer from those of Nowicki et al 3 who found sac-4 in 71% (10/14) of gonococcal strains isolated from patients with mixed gonococcal and chlamydial infection and 7% (1/14) in isolates from patients with gonococcal infection only. Using exact logistic regression analysis we have shown that there are significant diVerences in the prevalence of sac-4 between certain serovars.
Both epidemiological and biological factors may play a part in the occurrence of coexisting gonococcal and chlamydial infection. However our findings do not support a biological role for sac-4 in the development of mixed infection. 
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